John Siekierka

Prof. John Siekierka

Sokol Institute for Pharmaceutical Life Sciences and Department of Chemistry and Biochemistry, Montclair State University, Montclair, NJ 07043, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Molecular and Biochemical Parasitology
Verified
Journal Article
Closed access
APAkruti Patel
Akruti Patel
ACAgnieszka Nawrocka Chojnowski
Agnieszka Nawrocka Chojnowski
KGKatie Gaskill
Katie Gaskill
WMWilliam De Martini
William De Martini
RGRonald L. Goldberg
Ronald L. Goldberg
John SiekierkaJohn Siekierka
John Siekierka

9 February 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
STSreedhar Reddy Tummalapalli
Sreedhar Reddy Tummalapalli
RBRohit Bhat
Rohit Bhat
ACAgnieszka Chojnowski
Agnieszka Chojnowski
MPMonika Prorok
Monika Prorok
TKTamara Kreiss
Tamara Kreiss
DRDavid P. Rotella
David P. Rotella

15 July 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
DCDavid Calianese
David Calianese
TKTamara Kreiss
Tamara Kreiss
CKCanan Kasikara
Canan Kasikara
VDViralkumar Davra
Viralkumar Davra
KLKevin C Lahey
Kevin C Lahey
CAChoudhary Alok
Choudhary Alok
Phosphatidylserine (PS)-targeting monoclonal Abs (mAbs) that directly target PS and target PS via β2-gp1 (β2GP1) have been in preclinical and clinical development for over 10 y for the treatment of infectious diseases and cancer. Although the intended targets of PS-binding mAbs have traditionally included pathogens as well as stressed tumor cells and its associated vasculature in oncology, the effects of PS-targeting mAbs on activated immune cells, notably T cells, which externalize PS upon Ag stimulation, is not well understood. Using human T cells from healthy donor PBMCs activated with an anti-CD3 + anti-CD28 Ab mixture (anti-CD3/CD28) as a model for TCR-mediated PS externalization and T cell stimulation, we investigated effects of two different PS-targeting mAbs, 11.31 and bavituximab (Bavi), on TCR activation and TCR-mediated cytokine production in an ex vivo paradigm. Although 11.31 and Bavi bind selectivity to anti-CD3/28 activated T cells in a PS-dependent manner, surprisingly, they display distinct functional activities in their effect on IFN-γ and TNF-ɑ production, whereby 11.31, but not Bavi, suppressed cytokine production. This inhibitory effect on anti-CD3/28 activated T cells was observed on both CD4+ and CD8+ cells and independently of monocytes, suggesting the effects of 11.31 were directly mediated by binding to externalized PS on activated T cells. Imaging showed 11.31 and Bavi bind at distinct focal depots on the cell membrane. Collectively, our findings indicate that PS-targeting mAb 11.31 suppresses cytokine production by anti-CD3/28 activated T cells. Key Points PS-targeting mAbs 11.31 and Bavi bind external PS on anti-CD3/CD28 activated T cells. PS-binding mAb 11.31 suppresses anti-CD3/CD28 mediated cytokine production. Our findings implicate external PS as a regulatory target on activated T cells.

16 March 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
TKTamara Kreiss
Tamara Kreiss
TETyler Eck
Tyler Eck
BHBrittany Hart
Brittany Hart
STSreedhar Tummalapalli
Sreedhar Tummalapalli
DRDavid Rotella
David Rotella
John SiekierkaJohn Siekierka
John Siekierka
Filariasis, caused by a family of parasitic nematodes, affects millions of individuals throughout the tropics and is a major cause of acute and chronic morbidity. Current drugs are largely used in mass drug administration programs aimed at controlling the spread of disease by killing microfilariae, larval forms of the parasite responsible for transmission from humans to humans through insect vectors with limited efficacy against adult parasites. Although these drugs are effective, in some cases there are toxic liabilities. In case of loiasis which is caused by the parasitic eyeworm Loa loa, mass drug administration is contraindicative due to severe side effects of microfilariae killing, which can be life threatening. Our screening program and medicinal chemistry efforts have led to the identification of a novel series of compounds with potent killing activity against adult filarial parasites and minimal activity against microfilariae. A structural comparison search of our compounds demonstrated a close structural similarity to a recently described histone demethylase inhibitor, GSKJ1/4 which also exhibits selective adult parasite killing. We demonstrated a modification of histone methylation in Brugia malayi parasites treated with our compounds which might indicate that the mode of drug action is at the level of histone methylation. Our results indicate that targeting B. malayi and other filarial parasite demethylases may offer a novel approach for the development of a new class of macrofilaricidal therapeutics.